Plain-English translation of NCT07600268 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing whether stereotactic body radiotherapy (SBRT)—a type of high-dose radiation that precisely targets the tumor while protecting healthy tissue—works better when combined with maintenance chemotherapy compared to chemotherapy alone. You would be eligible if your pancreatic cancer has not grown or has shrunk after at least four months of initial chemotherapy. The study will compare how well patients do with the new treatment approach versus the standard approach.
Pancreatic cancer is difficult to treat and most patients are diagnosed too late for surgery. Even with chemotherapy, survival is often very short. Researchers believe that adding this specialized radiation therapy might help control the cancer better and possibly trigger the body's immune system to fight the cancer more effectively.
You likely qualify if…
You likely don't qualify if…
You would be randomly assigned to one of two groups: one group receives the specialized radiation therapy along with continued chemotherapy, and the other group continues with chemotherapy alone. The study will follow you for at least one year to track how well you respond to treatment, measure any side effects, and compare survival outcomes between the two groups. You'll have regular appointments for treatment, imaging scans, and blood work to monitor your progress.
AI-generated summary from trial data · Jun 4, 2026 · Not medical advice
China